- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00084318
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
A Phase II Randomized Trial Of Surgery Followed By Chemoradiotherapy Plus Cetuximab For Advanced Squamous Cell Carcinoma Of The Head and Neck
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Cisplatin and docetaxel may make the tumor cells more sensitive to radiation therapy. Combining a monoclonal antibody with chemoradiotherapy and giving them after surgery may kill any remaining tumor cells.
PURPOSE: This randomized phase II trial is studying adjuvant cetuximab given together with chemoradiotherapy using cisplatin to see how well it works compared to adjuvant cetuximab given together with chemoradiotherapy using docetaxel in treating patients with resected stage III or stage IV squamous cell carcinoma (cancer) or lymphoepithelioma of the head and neck.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
OBJECTIVES:
Primary
- Compare disease-free survival of patients with resected stage III or IV squamous cell carcinoma or lymphoepithelioma of the head and neck treated with adjuvant cetuximab in combination with chemoradiotherapy comprising docetaxel vs cisplatin.
Secondary
- Compare the safety and efficacy of these regimens in these patients.
- Compare locoregional control and overall survival rates in patients treated with these regimens.
- Correlate epidermal growth factor receptor (total and phosphorylated), pMAPK, pAKT, Stat-3, Ki-67, cyclo-oxygenase-2, and cyclin B1 expression with outcome in patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to Zubrod performance status (0 vs 1), risk category (positive margins vs high risk [i.e., ≥ 2 positive nodes or extracapsular nodal extension]) and use of intensity-modulated radiotherapy (no vs yes). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive cetuximab IV over 2 hours on day 1 (week 1). Patients then receive cetuximab IV over 1 hour and cisplatin IV over 1 hour before radiotherapy on days 8, 15, 22, 29, 36, and 43 (weeks 2-7). Patients undergo radiotherapy once daily, 5 days a week, beginning on day 8 for a total of 6 weeks (weeks 2-7).
- Arm II: Patients receive cetuximab and undergo radiotherapy as in arm I. Patients also receive docetaxel IV over 30 minutes before radiotherapy on days 8, 15, 22, 29, 36, and 43 (weeks 2-7).
Treatment in both arms continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 4 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 230 patients (115 per treatment arm) will be accrued for this study within approximately 29 months.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
- University of Alabama at Birmingham Comprehensive Cancer Center
-
Mobile, Alabama, Vereinigte Staaten, 36652-2144
- Mobile Infirmary Medical Center
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85013
- Arizona Oncology Services Foundation
-
Scottsdale, Arizona, Vereinigte Staaten, 85259-5499
- Mayo Clinic Scottsdale
-
Scottsdale, Arizona, Vereinigte Staaten, 85260
- Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea
-
Scottsdale, Arizona, Vereinigte Staaten, 85251
- Virginia G. Piper Cancer Center at Scottsdale Healthcare - Osborn
-
-
California
-
Auburn, California, Vereinigte Staaten, 95603
- Auburn Radiation Oncology
-
Burbank, California, Vereinigte Staaten, 91505
- Providence Saint Joseph Medical Center - Burbank
-
Cameron Park, California, Vereinigte Staaten, 95682
- Radiation Oncology Centers - Cameron Park
-
Carmichael, California, Vereinigte Staaten, 95608
- Mercy Cancer Center at Mercy San Juan Medical Center
-
Loma Linda, California, Vereinigte Staaten, 92354
- Loma Linda University Cancer Institute at Loma Linda University Medical Center
-
Mission Hills, California, Vereinigte Staaten, 91346-9600
- Providence Holy Cross Cancer Center
-
Oakland, California, Vereinigte Staaten, 94609
- CCOP - Bay Area Tumor Institute
-
Roseville, California, Vereinigte Staaten, 95661
- Radiation Oncology Center - Roseville
-
Sacramento, California, Vereinigte Staaten, 95815
- Radiological Associates of Sacramento Medical Group, Incorporated
-
Sacramento, California, Vereinigte Staaten, 95819
- Mercy General Hospital
-
Sacramento, California, Vereinigte Staaten, 95817
- University of California Davis Cancer Center
-
Torrance, California, Vereinigte Staaten, 90509
- Torrance Memorial Medical Center
-
Vacaville, California, Vereinigte Staaten, 95687
- Solano Radiation Oncology Center
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- University of Colorado Cancer Center at University of Colorado Health Sciences Center
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06511
- Hospital of Saint Raphael
-
-
Delaware
-
Newark, Delaware, Vereinigte Staaten, 19713
- CCOP - Christiana Care Health Services
-
-
Florida
-
Boca Raton, Florida, Vereinigte Staaten, 33486
- Lynn Regional Cancer Center at Boca Raton Community Hospital - Main Center
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33308
- Michael & Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Mayo Clinic - Jacksonville
-
Jacksonville, Florida, Vereinigte Staaten, 32207
- Baptist Cancer Institute - Jacksonville
-
Jupiter, Florida, Vereinigte Staaten, 33458
- Ella Milbank Foshay Cancer Center at Jupiter Medical Center
-
Miami, Florida, Vereinigte Staaten, 33136
- University of Miami Sylvester Comprehensive Cancer Center
-
Miami Beach, Florida, Vereinigte Staaten, 33140
- CCOP - Mount Sinai Medical Center
-
Orlando, Florida, Vereinigte Staaten, 32806
- M.D. Anderson Cancer Center Orlando
-
Tallahassee, Florida, Vereinigte Staaten, 32308
- Tallahassee Memorial Hospital
-
Tampa, Florida, Vereinigte Staaten, 33612-9497
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
-
-
Georgia
-
Columbus, Georgia, Vereinigte Staaten, 31904
- John B. Amos Cancer Center
-
Gainesville, Georgia, Vereinigte Staaten, 30501
- Northeast Georgia Medical Center
-
Savannah, Georgia, Vereinigte Staaten, 31403-3089
- Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
-
-
Illinois
-
Alton, Illinois, Vereinigte Staaten, 62002
- Saint Anthony's Hospital at Saint Anthony's Health Center
-
Harvey, Illinois, Vereinigte Staaten, 60426
- Ingalls Cancer Care Center at Ingalls Memorial Hospital
-
Maywood, Illinois, Vereinigte Staaten, 60153
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
-
Mount Vernon, Illinois, Vereinigte Staaten, 62864
- Good Samaritan Regional Health Center
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Cancer Institute at St. John's Hospital
-
-
Indiana
-
Elkhart, Indiana, Vereinigte Staaten, 46515
- Elkhart General Hospital
-
La Porte, Indiana, Vereinigte Staaten, 46350
- Center for Cancer Therapy at LaPorte Hospital and Health Services
-
South Bend, Indiana, Vereinigte Staaten, 46601
- Memorial Hospital of South Bend
-
South Bend, Indiana, Vereinigte Staaten, 46601
- CCOP - Northern Indiana CR Consortium
-
-
Iowa
-
Dubuque, Iowa, Vereinigte Staaten, 52001
- Wendt Regional Cancer Center at Finley Hospital
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536-0293
- Markey Cancer Center at University of Kentucky Chandler Medical Center
-
Lexington, Kentucky, Vereinigte Staaten, 40504
- John D. Cronin Cancer Center
-
-
Louisiana
-
Alexandria, Louisiana, Vereinigte Staaten, 71315-3198
- Tulane Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21231-2410
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital Cancer Center
-
Boston, Massachusetts, Vereinigte Staaten, 02118
- Cancer Research Center at Boston Medical Center
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Dana-Farber/Brigham and Women's Cancer Center
-
Fall River, Massachusetts, Vereinigte Staaten, 02721
- Hudner Oncology Center at Saint Anne's Hospital - Fall River
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106-0995
- St. Joseph Mercy Cancer Center at St. Joseph Mercy Hospital
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Josephine Ford Cancer Center at Henry Ford Hospital
-
Flint, Michigan, Vereinigte Staaten, 48503
- Hurley Medical Center
-
Flint, Michigan, Vereinigte Staaten, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Vereinigte Staaten, 49001
- Borgess Medical Center
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007-3731
- West Michigan Cancer Center
-
Marquette, Michigan, Vereinigte Staaten, 49855
- Upper Michigan Cancer Center at Marquette General Hospital
-
Saint Joseph, Michigan, Vereinigte Staaten, 49085
- Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph
-
-
Minnesota
-
Burnsville, Minnesota, Vereinigte Staaten, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Vereinigte Staaten, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- University of Minnesota Medical Center & Children's Hospital - Fairview
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Virginia Piper Cancer Institute at Abbott-Northwestern Hospital
-
Robbinsdale, Minnesota, Vereinigte Staaten, 55422-2900
- Hubert H. Humphrey Cancer Center at North Memorial Medical Center
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Mayo Clinic Cancer Center
-
Saint Cloud, Minnesota, Vereinigte Staaten, 56303
- CentraCare Clinic - River Campus
-
Saint Cloud, Minnesota, Vereinigte Staaten, 56303
- Coborn Cancer Center
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Park Nicollet Health Services
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- United Hospital
-
Waconia, Minnesota, Vereinigte Staaten, 55387
- Ridgeview Medical Center
-
-
Mississippi
-
Pascagoula, Mississippi, Vereinigte Staaten, 39581
- Regional Cancer Center at Singing River Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63701
- Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63701
- Saint Francis Medical Center
-
Kansas City, Missouri, Vereinigte Staaten, 64131
- CCOP - Kansas City
-
Saint Louis, Missouri, Vereinigte Staaten, 63141
- CCOP - St. Louis-Cape Girardeau
-
Saint Louis, Missouri, Vereinigte Staaten, 63141
- David C. Pratt Cancer Center at St. John's Mercy
-
Saint Louis, Missouri, Vereinigte Staaten, 63110
- Siteman Cancer Center at Barnes-Jewish Hospital
-
Springfield, Missouri, Vereinigte Staaten, 65804
- St. John's Regional Health Center
-
Springfield, Missouri, Vereinigte Staaten, 65807
- Hulston Cancer Center at Cox Medical Center South
-
-
Nebraska
-
Kearney, Nebraska, Vereinigte Staaten, 68848-1990
- Good Samaritan Cancer Center at Good Samaritan Hospital
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Methodist Cancer Center at Methodist Hospital - Omaha
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756-0002
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Camden, New Jersey, Vereinigte Staaten, 08103
- Cancer Institute of New Jersey at Cooper University Hospital - Camden
-
East Orange, New Jersey, Vereinigte Staaten, 07018-1095
- Veterans Affairs Medical Center - East Orange
-
Marlton, New Jersey, Vereinigte Staaten, 08053
- Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Saint Peter's University Hospital
-
Toms River, New Jersey, Vereinigte Staaten, 08755
- J. Phillip Citta Regional Cancer Center at Community Medical Center
-
Voorhees, New Jersey, Vereinigte Staaten, 08043
- Fox Chase Virtua Health Cancer Program at Virtua West Jersey
-
-
New York
-
Brooklyn, New York, Vereinigte Staaten, 11201
- Long Island College Hospital
-
Buffalo, New York, Vereinigte Staaten, 14263-0001
- Roswell Park Cancer Institute
-
New York, New York, Vereinigte Staaten, 10021
- Memorial Sloan-Kettering Cancer Center
-
Syracuse, New York, Vereinigte Staaten, 13210
- SUNY Upstate Medical University Hospital
-
-
North Carolina
-
Asheville, North Carolina, Vereinigte Staaten, 28801
- Mission Hospitals - Memorial Campus
-
Charlotte, North Carolina, Vereinigte Staaten, 28232-2861
- Blumenthal Cancer Center at Carolinas Medical Center
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Wayne Memorial Hospital, Incorporated
-
Greenville, North Carolina, Vereinigte Staaten, 27835-6028
- Leo W. Jenkins Cancer Center at ECU Medical School
-
Statesville, North Carolina, Vereinigte Staaten, 28677
- Iredell Memorial Hospital
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27103
- Forsyth Regional Cancer Center at Forsyth Medical Center
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44307
- McDowell Cancer Center at Akron General Medical Center
-
Akron, Ohio, Vereinigte Staaten, 44309-2090
- Akron City Hospital
-
Cincinnati, Ohio, Vereinigte Staaten, 45267
- Charles M. Barrett Cancer Center at University Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43210-1240
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
-
Mayfield Heights, Ohio, Vereinigte Staaten, 44124
- Hillcrest Cancer Center at Hillcrest Hospital
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239-3098
- Oregon Health & Science University Cancer Institute
-
-
Pennsylvania
-
Abington, Pennsylvania, Vereinigte Staaten, 19001
- Rosenfeld Cancer Center at Abington Memorial Hospital
-
Bryn Mawr, Pennsylvania, Vereinigte Staaten, 19010
- Bryn Mawr Hospital
-
East Stroudsburg, Pennsylvania, Vereinigte Staaten, 18301
- Dale and Frances Hughes Cancer Center at Pocono Medical Center
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033-0850
- Penn State Cancer Institute at Milton S. Hershey Medical Center
-
Paoli, Pennsylvania, Vereinigte Staaten, 19301-1792
- Cancer Center of Paoli Memorial Hospital
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19111-2497
- Fox Chase Cancer Center - Philadelphia
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107-5541
- Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15219
- Mercy Cancer Institute at Mercy Hospital
-
Reading, Pennsylvania, Vereinigte Staaten, 19612-6052
- Reading Hospital and Medical Center
-
Sayre, Pennsylvania, Vereinigte Staaten, 18840
- Guthrie Cancer Center at Guthrie Clinic Sayre
-
State College, Pennsylvania, Vereinigte Staaten, 16803
- Mount Nittany Medical Center
-
Wynnewood, Pennsylvania, Vereinigte Staaten, 19096
- CCOP - MainLine Health
-
Wynnewood, Pennsylvania, Vereinigte Staaten, 19096
- Lankenau Cancer Center at Lankenau Hospital
-
York, Pennsylvania, Vereinigte Staaten, 17405
- York Cancer Center at Apple Hill Medical Center
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
Greenville, South Carolina, Vereinigte Staaten, 29615
- CCOP - Greenville
-
Greenville, South Carolina, Vereinigte Staaten, 29601
- Bon Secours St. Francis Health System
-
Spartanburg, South Carolina, Vereinigte Staaten, 29303
- CCOP - Upstate Carolina
-
Spartanburg, South Carolina, Vereinigte Staaten, 29303
- Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
-
-
South Dakota
-
Rapid City, South Dakota, Vereinigte Staaten, 57701
- Rapid City Regional Hospital
-
-
Tennessee
-
Kingsport, Tennessee, Vereinigte Staaten, 37662
- Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center
-
Knoxville, Tennessee, Vereinigte Staaten, 37916
- Thompson Cancer Survival Center
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030-4009
- M.D. Anderson Cancer Center at University of Texas
-
Temple, Texas, Vereinigte Staaten, 76508
- CCOP - Scott and White Hospital
-
-
Utah
-
Murray, Utah, Vereinigte Staaten, 84107
- Cottonwood Hospital Medical Center
-
Ogden, Utah, Vereinigte Staaten, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, Vereinigte Staaten, 84604
- Utah Valley Regional Medical Center - Provo
-
Saint George, Utah, Vereinigte Staaten, 84770
- Dixie Regional Medical Center - East Campus
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Huntsman Cancer Institute at University of Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84106
- Utah Cancer Specialists at UCS Cancer Center
-
Salt Lake City, Utah, Vereinigte Staaten, 84143
- Latter Day Saints Hospital
-
-
Virginia
-
Danville, Virginia, Vereinigte Staaten, 24541
- Danville Regional Medical Center
-
Richmond, Virginia, Vereinigte Staaten, 23249
- Veterans Affairs Medical Center - Richmond
-
Richmond, Virginia, Vereinigte Staaten, 23298-0037
- Virginia Commonwealth University Massey Cancer Center
-
-
Washington
-
Bellingham, Washington, Vereinigte Staaten, 98225
- St. Joseph Cancer Center
-
Seattle, Washington, Vereinigte Staaten, 98101
- CCOP - Virginia Mason Research Center
-
Seattle, Washington, Vereinigte Staaten, 98195-6043
- University Cancer Center at University of Washington Medical Center
-
-
West Virginia
-
Wheeling, West Virginia, Vereinigte Staaten, 26003
- Schiffler Cancer Center at Wheeling Hospital
-
-
Wisconsin
-
Green Bay, Wisconsin, Vereinigte Staaten, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, Vereinigte Staaten, 54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay, Wisconsin, Vereinigte Staaten, 54303
- St. Mary's Hospital Medical Center - Green Bay
-
Green Bay, Wisconsin, Vereinigte Staaten, 54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital
-
La Crosse, Wisconsin, Vereinigte Staaten, 54601
- Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Vereinigte Staaten, 53792-6164
- University of Wisconsin Comprehensive Cancer Center
-
Marinette, Wisconsin, Vereinigte Staaten, 54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Medical College of Wisconsin Cancer Center
-
Racine, Wisconsin, Vereinigte Staaten, 53405
- All Saints Cancer Center at All Saints Healthcare
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Histologically confirmed squamous cell carcinoma of the head and neck meeting the following criteria:
- Site of tumor origin in the oral cavity, oropharynx, larynx, or hypopharynx (excluding lip, nasopharynx, or sinuses)
Gross total resection must be completed within 7 weeks of randomization, with pathology demonstrating one or more of the following risk factors:
- Histologic extracapsular nodal extension
- Histologic involvement of ≥ 2 regional lymph nodes
- Invasive cancer seen on microscopic evaluation of the resection margin, with no evidence of gross tumor residual.
- Tonsillar cancer patients who undergo transoral excision of all gross tumor are eligible provided extracapsular nodal extension or involvement of ≥ 2 regional lymph nodes is histologically confirmed
- American Joint Committee on Cancer (AJCC) pathological stage III or IV
- No evidence of distant metastases
- No synchronous or concurrent head and neck primary tumors
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Zubrod 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count ≥ 2,000/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin > 8.0 g/dL
Hepatic
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT), and alkaline phosphatase meeting 1 of the following parameters:
- Alkaline phosphatase ≤ ULN AND AST or ALT ≤ 5 times ULN
- Alkaline phosphatase ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN
- Alkaline phosphatase ≤ 5 times ULN AND AST or ALT ≤ ULN
Renal
- Creatinine ≤ 1.5 mg/dL
Cardiovascular
- No unstable angina
- No uncontrolled hypertension
- No myocardial infarction within the past 6 months (unless successfully treated with coronary artery bypass surgery or percutaneous transluminal coronary angioplasty)
- No uncontrolled arrhythmia
- No congestive heart failure
- No more than 2 heart-related hospitalizations within the past year
- No other active cardiac disease
Pulmonary
- No more than 2 hospitalizations for chronic obstructive pulmonary disease within the past year
Neurologic
- No pre-existing peripheral neuropathy ≥ grade 2
- No uncontrolled seizure disorder
- No active neurological disease
Other
- No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
- No other invasive malignancy within the past 3 years except nonmelanoma skin cancer
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior anti-epidermal growth factor receptor antibody therapy
Chemotherapy
- More than 3 years since prior cytotoxic chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- No prior head and neck radiotherapy
Surgery
- See Disease Characteristics
Other
- No prior tyrosine kinase inhibitor therapy
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: RT + cisplatin + cetuximab
Loading dose of cetuximab followed by radiation therapy with weekly cisplatin and cetuximab.
|
400 mg/m^2 intravenously over 120 minutes on day 1 (week 1) followed by 250 mg/m^2 intravenously over 60 minutes in weeks 2 through 7.
30 mg/m^2 intravenously infused over over 60 minutes in weeks 2 through 7.
60 Gy (2 Gy once a day, 5 times a week)
|
|
Experimental: RT + docetaxel + cetuximab
Loading dose of cetuximab followed by radiation therapy (RT) with weekly docetaxel and cetuximab.
|
400 mg/m^2 intravenously over 120 minutes on day 1 (week 1) followed by 250 mg/m^2 intravenously over 60 minutes in weeks 2 through 7.
60 Gy (2 Gy once a day, 5 times a week)
15 mg/m^2 intravenously infused over 30 minutes in weeks 2 through 7.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Disease-free Survival
Zeitfenster: From randomization to 2 years
|
Two-year rates are shown (Kaplan-Meier estimates).
Disease-free survival is defined as the time from randomization to local, regional, or distant progression, second primary, or death (event) or last follow-up (censored).
Response criteria as follows: No evidence of disease (NED): All patients must have no measurable tumor following surgery; Local-Regional Relapse: Recurrent cancer in the tumor bed and/or neck not clearly attributable to a second primary neoplasm; biopsy confirmation is necessary; Distant Relapse: Clear evidence of distant metastases (lung, bone, brain, etc.); Biopsy is recommended where possible.
A solitary lung mass/nodule is considered a second primary neoplasm unless proven otherwise.
|
From randomization to 2 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Overall Survival
Zeitfenster: From randomization to 2 years
|
Two-year rates are shown (Kaplan-Meier estimates).
Overall survival is defined as the time from randomization to death (event) or last follow-up (censored).
|
From randomization to 2 years
|
|
Treatment Tolerance
Zeitfenster: From start of treatment to end of treatment (protocol treatment lasts seven weeks).
|
Tolerability was defined as having received 90% of the radiation dose, 95% of the cetuximab loading dose, and at least 4 weeks of cetuximab and cisplatin or docetaxel at doses 95% of the protocol prescription.
The percentage of patients determined to be tolerant of treatment are shown.
|
From start of treatment to end of treatment (protocol treatment lasts seven weeks).
|
|
Frequency of Toxicity (Grade 5 and Acute Non-hematologic Grade 4)
Zeitfenster: From start of treatment to last follow-up. Analysis occurs at the time of the primary analysis.
|
Each regimen was monitored for excessive acute toxicity (defined as nonhematologic grade 4 toxicity within 90 days of the start of radiation or any grade 5 toxicity).
The target rate was based on the observed rate from RTOG-9501/NCT00002670 of 15%.
The unacceptable rate was >30%.
[RTOG = Radiation Therapy Oncology Group]
|
From start of treatment to last follow-up. Analysis occurs at the time of the primary analysis.
|
|
Frequency of Other Acute and Late Toxicity
Zeitfenster: From start of treatment to last follow-up. Analysis occurs at the time of the primary endpoint analysis.
|
Maximum grade toxicity that is definitely, probably, or possibly related to protocol treatment.
|
From start of treatment to last follow-up. Analysis occurs at the time of the primary endpoint analysis.
|
|
Local-regional Control
Zeitfenster: From randomization to 2 years
|
Two-year rate is shown (cumulative incidence estimate).
Local-regional failure is defined as the time from randomization to local-regional recurrence (event), death (competing risk), or last follow-up (censored).
|
From randomization to 2 years
|
|
Correlation of EGFR (Total and Phosphorylated) pMAPK, pAKT, Stat-3, KI-67, COX-2, and Cyclin B1 Expression With Local-regional Control, and Overall and Disease-free Survival
Zeitfenster: From randomization to two years
|
From randomization to two years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Paul M. Harari, MD, University of Wisconsin, Madison
- Studienstuhl: Jeffrey N. Myers, MD, PhD, FACS, M.D. Anderson Cancer Center
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Harari PM, Harris J, Kies MS, et al.: Phase II randomized trial of surgery followed by chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). [Abstract] Int J Radiat Oncol Biol Phys 69 (3 Suppl): A-22, S13, 2007.
- Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, Foote RL, Machtay M, Rotman M, Khuntia D, Straube W, Zhang Q, Ang K. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014 Aug 10;32(23):2486-95. doi: 10.1200/JCO.2013.53.9163. Epub 2014 Jul 7.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
- Plattenepithelkarzinom des Oropharynx im Stadium III
- Stadium III Lymphoepitheliom des Oropharynx
- Plattenepithelkarzinom des Oropharynx im Stadium IV
- Stadium IV Lymphoepitheliom des Oropharynx
- Plattenepithelkarzinom im Stadium III des Hypopharynx
- Plattenepithelkarzinom des Hypopharynx im Stadium IV
- Plattenepithelkarzinom des Kehlkopfes im Stadium III
- Plattenepithelkarzinom des Kehlkopfes im Stadium IV
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach histologischem Typ
- Neubildungen
- Neubildungen, Drüsen und Epithelien
- Neubildungen, Plattenepithelzellen
- Karzinom
- Karzinom, Plattenepithel
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antineoplastische Mittel
- Tubulin-Modulatoren
- Antimitotische Mittel
- Mitose-Modulatoren
- Antineoplastische Mittel, immunologische
- Docetaxel
- Cisplatin
- Cetuximab
Andere Studien-ID-Nummern
- RTOG-0234
- CDR0000360850
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .